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Abstract
In vivo suppression of glioblastoma multiforme (GBM) in Wistar rats using silica-shelled biocatalytic
Pt(NH3)4Cl2 nanoparticles is reported. These nanoparticles were synthesized by a sol-gel technique and
characterized by SEM and HRTEM imaging. We confirmed morphological uniformity (30 nm) and surface
acidity of the nanoparticles, respectively, by TEM imaging and FTIR spectral analysis. Interestingly,
treatment of Wistar rats intraperitoneally inoculated with C6 cells using the biocatalysts resulted in
considerable tumor shrinkage. Efficiency of the biocatalyst to shrink a tumor is superior to that by the
commercial cytotoxic agent cisplatin. The tumor suppression property of Pt(NH3)4Cl2 nanoparticles is
attributed to catalytic damage of DNA in C6 cells.
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C
ontrolled drug delivery to the brain date back to
the 1970s, when Chisholm and Singer (1) used a
cannula to release fluids directly into the central
nervous system (CNS) of rats without any perceptible
harm to the animal. These studies generated great interest
in the administration of drugs with microinjections in
specific areas (2 5). Recently, the use of nanoparticles for
cancer treatment has attracted much attention, mainly in
the drug delivery (6) and photodynamic therapy fields
(7). Doxorubicine, BCNU (8), methotrexate, and 5-FU
are chemotherapeutic agents that are extensively encap-
sulated in a great variety of nanoparticles.
Due to the blood brain barrier (BBB), only a small
number of chemotherapeutic agents are suitable for the
treatment of brain tumors (9). Currently Temozolomide
is the best well-tolerated drug that can cross BBB (10 13).
In the case of malignant tumors like glioblastoma multi-
forme (GBM) (13 16), Temozolomide can improve life
expectancy by 6 months. Because GBM spreads very
rapidly and infiltrates healthy tissue, complete resection is
practically impossible, leaving the survival index of
patients with GBM rather low even after surgery, radio-
therapy, and chemotherapy.
Duetoitswell-knownDNAreactivity,cisplatinexhibits
high antitumoral activity and is one of the most widely
accepted chemotherapeutic agent in the treatment of
several cancers. However, some recent reports show
that only cis-conformations of platinum complexes are
effective against cancer (17, 18). Here we report in vivo
suppression of GBM in Wistar rats treated with silica-
shelled tetraminedichloro platinum(II) nanoparticles.
These nanoparticles were prepared by incorporating
tetraminedichloro platinum(II) in silica shells by a sol-
gel process. We investigated relations among acidic sites
on the nanoparticles, in vivo interactions between Pt-
supported nanoparticles and DNA in C6 cells, and tumor
suppression.
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We examined the morphology and structure of
Pt(NH3)4Cl2/SiO2 nanoparticles by SEM and TEM
imaging and energy dispersive spectroscopy (EDS).
A typical SEM image of Pt(NH3)4Cl2/SiO2 nanoparticles
is shown in Fig. 1a. Morphology of the material indicates
agglomeration of small particles into non-uniform
nanostructures. High resolution TEM image provided
us with evidence for B1 nm diameter Pt(NH3)4Cl2
complexes embedded in silica shells (Fig. 1c). These
nanoparticles were further characterized by an EDS
analysis, which indicates the presence of silicon, oxygen,
platinum, and chlorine (supplementary information).
We investigated in vivo suppression of C6 tumor in a
Wistar rat using the biocatalytic Pt(NH3)4Cl2/SiO2
nanoparticles. At first, C6 cells (obtained from the
American Tissue Culture Collection, Rockville, MD)
were cultured into sufficient quantity and, subsequently,
1   10
7 C6 cells were intraperitoneally inoculated in a
Wistar strain male rat in order to develop a GBM type
tumor. Twenty days after inoculation the C6 tumor had
grown to an acceptable size in 80% of the animals (19).
When the rats developed a tumor of 2 cm, they were
randomly allocated into four groups as follows: (A)
control (no administration), (B) administered with a
suspension of the Pt complex, (C) administered with a
suspension of sol-gel silica nanoparticles, and (D)
administered with a suspension of Pt(NH3)4Cl2/SiO2
nanoparticles. Twenty-one days after the administration
of these nanoparticles, tumors were surgically extracted
and analyzed ex vivo. Also, we examined the effect of in
vivo administered nanoparticles on tumor size. We found
that suppression of the tumor was negligible in the group
of rats administered with the Pt complex or sol-gel silica
nanoparticles. On the other hand, a decrease in the tumor
size (approximately a 73% reduction) was significant in
the group of rats administered with sol-gel Pt(NH3)4Cl2/
SiO2 nanoparticles. We attribute that the tumor suppres-
sion activity of sol-gel Pt(NH3)4Cl2/SiO2 nanoparticles
comes from killing of cancer cells via free radicals
inducing DNA damage. In other words, the biocatalytic
nanoparticles were possibly taken up by cancer cells and
free radical centers on the surface of the nanoparticles
inducing cell death via DNA damage. These possibilities
investigated by ex vivo analysis of tumor sections
and ex vivo and in vitro analyses of DNA damage in C6
cancer cells.
The H-E micrographs of histological sections from
tumors after treatment with Pt(NH3)4Cl2/SiO2 nanopar-
ticles are shown in Fig. 2. We analyzed different tumor
regions at low and high magnifications. Histological
studies were conducted following the path of injection
to associate direct action of nanoparticles with tumor
suppression. Fig. 2b shows the area in H-E stained
sections from the C6 tumor with viable tumor cells where
200 nm
(a) (b) (c)
Fig. 1. (a) Scanning electron micrograph and (b and c) TEM images of Pt(NH3)4Cl2/SiO2 nanoparticles. Arrows in (c) indicate
Pt(NH3)4Cl2 complexes embedded in silica shells.
Fig. 2. H-E stained sections from the C6 tumor in a Wistar
rat treated with Pt(NH3)4Cl2/SiO2.( a  c) Low magniﬁcation
and (d h) high magniﬁcation.
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In Fig. 2d, two different zones are observed: the upper
region consists more of viable tumor cells; whereas, cell
damage is remarkable in the lower region. The tumor
suppression by Pt(NH3)4Cl2/SiO2 nanoparticles is clearly
presented at a higher magnification in Fig. 2h, which is
indicative of a chemotherapeutic effect of the nanopar-
ticles. On the other hand, we could not identify any
remarkable changes to tumors in control animals (group
A C).
The in vivo effect of Pt(NH3)4Cl2/SiO2 nanoparticles on
the C6 tumor was examined by the cell viability assay of
an extracted tumor using Trypan blue. In this assay, live
cells exclude Trypan blue dye by retarding its intracellular
diffusion; whereas, the dye effectively enters inside dead
cells because of their poor cell wall integrity. Fig. 3 shows
histological images of a C6 tumor in vivo treated with
Pt(NH3)4Cl2/SiO2 nanoparticles. Remarkable intensity of
the stain is indicative of anticancer activity of the
nanoparticles. Dead cells in the C6 tumor are clearly
identified in images at higher magnification (Fig. 3c h).
We assume that the anticancer activity of Pt(NH3)4Cl2/
SiO2 nanoparticles originates as a result of intracellular
uptake of the nanoparticles, interactions of the nano-
particles with genetic materials, and subsequent damage
of DNA.
We examined DNA damage for C6 cells in tumors
treated with the biocatalytic nanoparticles by analyzing
terminal transferase (TUNEL assay). In the TUNEL
assay, end labeling techniques are employed for studying
the actual mechanism of DNA fragmentation, as well as
the detection and characterization of endonucleases.
Endonucleases cleave DNA by attacking the phosphodie-
ster bonds of the sugar phosphate backbone of each
strand. The phosphodiester bond can be cleaved in two
ways such that the phosphate is left on either the 3? end of
the DNA strand or the 5? end, the opposite end being left
with a hydroxyl group in each case. The TUNEL image of
aC 6 tumor is shown in Fig. 4. The white dots observed in
Fig. 3. Trypan blue histological images of sections from
C6 tumors in Wistar rats treated with Pt(NH3)4Cl2/SiO2
nanoparticles. (a c) Low magniﬁcation and (d h) high
magniﬁcation.
Fig. 4. Representative TUNEL images from a C6 tumor:
(a) Tumor treated using Pt(NH3)4Cl2/SiO2 and (b c) higher
magniﬁcation.
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TUNEL technique is widely used to quantify apoptotic
cells, because it allows identifying affected cells. This
technique detects DNA fragmentation by endogenous
DNA, the final step in apoptosis. In order to identify the
cell death process (apoptosis or necrosis), a specific
fluorescent enzyme is used to mark the ends of the
fragmented DNA. This is characteristic of cell death by
apoptosis (programmed cell death), instead of necrosis in
which the membrane collapses and cells are rapidly
destroyed. Therefore, the white dots in Fig. 4 is indicative
of DNA fragmentation in tumors treated with Pt(NH3)4
Cl2/SiO2 nanoparticles. The effect of Pt(NH3)4Cl2/SiO2
nanoparticles on DNA damage and fragmentation was
confirmed from in vitro treatment of C6 cells with the
nanoparticles (supplementary information).
In summary, we developed a new biocatalytic nano-
particle for the treatment of tumors. Wistar rats intraper-
itoneally inoculated with C6 cancer cells and treated with
the biocatalyst resulted in nearly 73% shrinkage of the
tumor. The tumor suppression is due to the killing of
cancer cells via intracellular uptake and DNA fragmenta-
tion. The small dimension of the SiO2 particles along
with Pt(NH3)4Cl2 enable intracellular uptake of the
nanoparticles. Also, the uniform porous nature of
supported Pt(NH3)4Cl2/SiO2 with small particle size
(1 2 nm) is likely the prerequisite for an efficient catalytic
degradation of DNA in cancer cells. These results suggest
that administration of chemotherapeutic nanoparticles
can be an effective treatment for aggressive tumors such
as GBM. We firmly believe that a new chapter in catalytic
nanomedicine has been opened in the chemotherapeutic
treatment of malignant tumors through the use of
biocatalytic nanoparticles.
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